Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted.
|
30537486 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temozolomide (TMZ) is the first-line chemotherapy drug for glioma, but whether TMZ should be withheld from patients with GBMs that lack O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promoter methylation is still under debate.
|
31611911 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
|
31108342 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation of the O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) promoter has emerged as strong prognostic factor in the therapy of glioblastoma multiforme.
|
31766430 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Independent overall survival predictors were MGMT promoter methylation (adjusted HR 0.35; 95% CI 0.23-0.55) and a RTV of <3.50 cc (adjusted HR 0.53; 95% CI 0.29-0.95), but not EOR for incompletely resected glioblastomas.
|
30712777 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Enrichment analyses of intragenic DNA methylation profiles with epigenetic signatures prioritized the intragenic DNA methylation of ZMIZ1 as a possible glioblastoma prognostic marker that is independent of MGMT methylation in IDH1 wild-type patients.
|
31373686 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show the changes of nuclear proteome in the MGMT-deficient GBM U87 cells treated with TMZ for 1 week.
|
31833081 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MGMT is frequently downregulated in cancer cells (up to 40% in glioblastomas), which is due to CpG promoter methylation.
|
31039537 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
|
31208813 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This study aimed to detect imaging parameters to predict MGMT promoter methylation in GBs by using a commercially available software.
|
30673883 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Instead, a difference in survival outcomes was confirmed in unmethylated-MGMT GB patients with better survival for patients undergoing to SDRT, particularly in sub-total resection.
|
31325903 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The absence of systematic and clinically relevant changes in HRQOL and neurocognitive function combined with the survival benefit of lomustine-temozolomide versus temozolomide alone suggests that a long-term net clinical benefit exists for patients with newly diagnosed glioblastoma with methylation of the MGMT promoter and supports the use of lomustine-temozolomide as a treatment option for these patients.
|
31488360 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, PTEN deletion had poor prognostic value in astrocytomas IDH-wildtype (p = 0.015), while in GBM IDH-wildtype was associated with better overall survival (p = 0.042) as well as MGMT promoter methylation (p = 0.009).
|
31623593 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
|
30549269 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
|
31413318 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma.
|
30579113 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This was not the case in glioblastoma cells expressing the repair protein MGMT, suggesting that the primary DNA lesion responsible for triggering HIPK2-mediated apoptosis is <i>O<sup>6</sup></i> -methylguanine.
|
30796178 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation status of the O<sup>6</sup>-methylguanine DNA methyltransferase (<i>MGMT</i>) gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM).
|
30514777 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
|
30121967 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
|
30189035 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
|
30399573 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ).
|
31325144 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, because temozolomide did not cause phosphorylation of cPLA<sub>2</sub> in MGMT high-expressing glioblastoma T98G cells, phosphorylation of cPLA<sub>2</sub> may be caused by DNA alkylation of temozolomide.
|
31442413 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study offers novel insights for improving therapeutic management of MGMT-deficient glioblastoma.
|
31347685 |
2019 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma.
|
31594994 |
2019 |